000 01557 a2200433 4500
005 20250514071904.0
264 0 _c20030725
008 200307s 0 0 eng d
022 _a0006-3223
024 7 _a10.1016/s0006-3223(02)01599-8
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aThompson, Peter M
245 0 0 _aElevated cerebrospinal fluid SNAP-25 in schizophrenia.
_h[electronic resource]
260 _bBiological psychiatry
_cJun 2003
300 _a1132-7 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAntipsychotic Agents
_xadministration & dosage
650 0 4 _aBiomarkers
_xcerebrospinal fluid
650 0 4 _aCase-Control Studies
650 0 4 _aDopamine Antagonists
_xadministration & dosage
650 0 4 _aExocytosis
650 0 4 _aHaloperidol
_xadministration & dosage
650 0 4 _aHumans
650 0 4 _aMembrane Proteins
_xcerebrospinal fluid
650 0 4 _aMiddle Aged
650 0 4 _aNerve Tissue Proteins
_xcerebrospinal fluid
650 0 4 _aPsychiatric Status Rating Scales
650 0 4 _aSchizophrenia
_xcerebrospinal fluid
650 0 4 _aSpinal Puncture
650 0 4 _aSynaptic Transmission
650 0 4 _aSynaptosomal-Associated Protein 25
700 1 _aKelley, Mary
700 1 _aYao, Jeffrey
700 1 _aTsai, Guochuan
700 1 _avan Kammen, Daniel P
773 0 _tBiological psychiatry
_gvol. 53
_gno. 12
_gp. 1132-7
856 4 0 _uhttps://doi.org/10.1016/s0006-3223(02)01599-8
_zAvailable from publisher's website
999 _c12598533
_d12598533